ClinicalTrials.gg
RecruitingNCT04713917EPIONE-01Updated Nov 28, 2023

Evaluation of Innovative Therapeutic Approaches of Vaginal and Sexual Dysfunction After Breast Cancer Treatment

An interventional study of Hyaluronique Acid Gel and Laser CO2 in Breast Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris — 10 open to participants now, 13 under way, none of them phase 3. Breast Neoplasms · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
3rd of 13
330 · median 72
Started
2021
with 1 other
No phase
10 of 32
1 open now
Primary completion
2024-02
later than 0 of 12 live
Registered
19th of 32
by date

Among the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 10 with no phase, reaches primary completion later than 0 of the 12 other live ones, and was the 19th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

10 of the 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Many studies have shown that locoregional treatment (surgery, radiotherapy) and systemic treatment (endocrine therapy and chemotherapy) for breast cancer (BC) may impact sexuality by causing physical and/or psychological damages.

Approximately 50-75 % of BC survivors suffer from vulvovaginal atrophy (VVA). The earliest symptoms of VVA are decreased vaginal lubrication, followed by other vaginal and urinary symptoms, such as burning, itching, bleeding, leucorrhoea, dyspareunia and dysuria symptoms. Various surveys have shown that VVA symptoms lead to female sexual disorder and on their partners through sexual unsatisfactory. However, it appears that sexuality is a little discussed topic during the follow-up of BC survivors. Most of patients relate a poor satisfaction with information and counselling related to sexuality and vaginal health, which are denied by many practitioners.

Patients treated for BC cannot find relief in hormonal replacement therapy (HRT), which is considered the gold standard treatment for VVA symptoms. The usual treatments for these women are topics such as ovula or gel (lubricant, hyaluronic acid (HA)...) with however, a short term effect even when these topics are applied regularly and correctly during at least 2 to 3/weeks.In the literature, there is a significant impact on VVA at one month but later data are lacking . Moreover, patients' compliance and daily application are paramount of importance for efficacy that could disappear when the treatment is stopped.

No randomized controlled trial has compared this treatment to innovative strategies. In this context, it is important to establish management strategies for VVA and sexual disorder after BC.

Our objective is to assess prevalence rate of VVA among breast cancer survivors after the loco regional treatment and chemotherapy, and to compare the efficacy of innovative treatments namely, new biophysical inductor (Laser CO2) and chemical bio inductor (Hyaluronic acid injections) treatments to the efficacy of standard non-hormonal topic treatment for improving the VVA and the quality of sexual life on a long-term.

Read the detailed description

An open-label multicentre controlled trial randomized in 3 parallel groups (1:1:1) to assess the one-year superiority of bio physical inductor (C02 laser, D0 and M6, group laser) compared to the standard treatment currently recommended (Mucogyne, 2 times a week for one year, control group) in the one hand, and of chemical bio inductor (Desirial, injection of 1 mL of hyaluronic acid in the first 3 cm of the vaginal walls, D0 and M6, HA injection group) compared to the control group in the other hand in BC survivors with VVA, with blinded primary endpoint assessment.

The use of these innovative treatments (lasers and injections) for Vulvovaginal atrophy based on the bio induction and the regenerative medicine could improve the quality of the vaginal mucosa after breast cancer therapy and could be a new strategy for these women who cannot benefit from Hormone Replacement Therapy (HRT). The benefits expected are the improvement of the quality of vulvo-vaginal mucosa and the improvement of the sexual quality of life of the patient.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Locoregional and systemic treatment
  • Vulvovaginal atrophy
  • Sexual quality of life
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who present VVA with a vaginal health index \< 15
  • 18 years ≤ Age ≤ 75 years
  • Patient with non- breast cancer
  • End of loco-regional treatments (surgery+/- radiotherapy) and chemotherapy for 6 months
  • Patients with no psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Written consent
  • Affiliation to a social security system

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding woman (A Urinary bHCG will be performed for no menopausal women)
  • Vulvo vaginal area showing signs of clinical inflammation and/or viral infection (e.g.: Papilloma, Herpes), bacterial, fungal.
  • Abnormal vaginal smear within 3 years before inclusion
  • History of vulvo vaginal cancer
  • History of Papilloma virus
  • History of vaginal herpes
  • Use of topical hyaluronic acid application in the month before inclusion
  • History of allergy to HA
  • to the components of Mucogyne®, and Desirial®
  • Patients with tendency to develop hypertrophic scars
  • No , or no efficient contraception(for women with non-menopausal status)
  • Patients under legal protection
  • Prisoners
  • Participation to another interventional study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Active comparator
    Gel Group

    Two applications of HA gel (Mucogyne®) per week during one year.

    Device: Hyaluronique Acid Gel

  • Experimental
    Laser Group

    Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.

    Device: Laser CO2

  • Experimental
    HA Injection Group

    Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).

    Device: Hyaluronique Acid Injection

Interventions

  • DeviceHyaluronique Acid Gel

    Vaginal gel based on HA with liposomal structure applicated 2 times a week

  • DeviceLaser CO2

    The laser energy delivered along the vaginal wall heats the tissue without damaging it.

  • DeviceHyaluronique Acid Injection

    HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.

06

What researchers measure

Primary outcomes

  1. Rate of women free from vulvo-vaginal atrophy on the basis of a vaginal health index (VHI) ≥ 15.

    Time frame: at 12 months

Secondary outcomes

  1. Comparisons among groups of VHI score (absolute and relative changes in the VHI)

    Time frame: Day 0 to 12 months

  2. Female Sexual Distress (FSD) SCALE

    Time frame: Day 0 to 12 months

  3. Evaluation of the pain during treatment (Visual Analogue Scale (EVA))

    Time frame: Day 0 to 12 months

  4. Rate of adverse effects

    Time frame: Day 0 to 12 months

  5. compliance in the control treatment by the count of forgetfulness during the treatment per topical gel

    Time frame: Day 0 to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2024, 35 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 35 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2021
First posted
Jan 19, 2021
StartActual
Feb 21, 2021
Primary completionEst.
Feb 1, 2024
CompletionEst.
Feb 1, 2024
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04713917
Collaborators
INTERmedic, Laboratoires Vivacy, Laboratoires IPRAD PHARMA
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Feb 21, 2021
Primary completion
Feb 1, 2024 (estimated)
Completion
Feb 1, 2024 (estimated)
Last update
Nov 28, 2023

Study contacts

Barbara HERSANT, MD
Contact
barbara.hersant@aphp.fr
1 49 81 45 33 ext. +33
Yazid BELKACEMI, MD, PhD
Contact
yazid.belkacemi@aphp.fr
1 49 81 45 22 ext. +33
Barbara HERSANT, MD
study director · Assistance Publique - Hôpitaux de Paris
Yazid BELKACEMI, MD, PhD
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion